ClinicalTrials.gg
RecruitingNCT05967663Updated Dec 4, 2023

Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)

An interventional study of PCI-immediate complete revascularisation and PCI-staged complete revascularisation in ST Elevation Myocardial Infarction, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital — 2 open to participants now, 2 under way, none of them phase 3. ST Elevation Myocardial Infarction · RenJi Hospital.

Started
2023
the only one that year
No phase
3 of 13
2 open now
Registered
11th of 13
by date

Among the 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital, this one is the only one that started in 2023, is one of 3 with no phase, and was the 11th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

2 of the 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in ST Elevation Myocardial Infarction by RenJi Hospital, or all of them as a file.
02

Study summary

It is a prospective, multicenter, randomised controlled, open-label, blinded endpoint assessment trial, to compare the strategy of immediate complete revascularisation and staged complete revascularisation in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.

Read the detailed description

Objectives: The purpose of this study is to investigate whether FFR guided PCI strategy for non-culprit lesions should be attempted during the index procedure or staged in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Patients presenting STEMI and multivessel coronary disease successful primary PCI of the culprit lesion (including those who still have ischemic symptoms within 48 hours)
  3. Multivessel disease was defined at least one non-culprit coronary arteries with a diameter of 2.5 mm or more and a maximum diameter at least 50% stenosis by visual estimation, PCI can be successfully implemented
  4. Sign an informed consent form before participating in the study

Exclusion Criteria:

  1. Received thrombolytic therapy
  2. Cardiac shock or SBP\<90mmHg;
  3. History of old myocardial infarction;
  4. Left main artery lesion, non infarct related vessels are CTO lesions;
  5. PCI in the previous 30 days or Previous CABG
  6. Patients who cannot give informed consent or have a life expectancy of less than 1 year
  7. Patients combined with other serious diseases such as severe renal dysfunction (creatinine clearance value\<30ml/min;), liver dysfunction and thrombocytopenia
  8. Patients with severe valve disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension;
  9. Not suitable for clinical research:

    1. . Currently participating in another study that may affect the primary endpoint
    2. . Pregnant and lactating women;
    3. . Known allergy to drugs that may be used in the study;
    4. . Unable to comply with the trial protocol or follow-up requirements; Or the researcher believes that participating in the trial may result in patients facing greater risks.
03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • STEMI
  • Coronary Artery Disease
  • Coronary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patients presenting STEMI and multivessel coronary disease successful primary PCI of the culprit lesion (including those who still have ischemic symptoms within 48 hours)
  3. Multivessel disease was defined at least one non-culprit coronary arteries with a diameter of 2.5 mm or more and a maximum diameter at least 50% stenosis by visual estimation, PCI can be successfully implemented
  4. Sign an form before participating in the study

Exclusion criteria

Exclusion Criteria:

  1. Received thrombolytic therapy
  2. Cardiac shock or SBP\<90mmHg;
  3. History of old myocardial infarction;
  4. Left main artery lesion, non infarct related vessels are CTO lesions;
  5. PCI in the previous 30 days or Previous CABG
  6. Patients who cannot give or have a of less than 1 year
  7. Patients combined with other serious diseases such as severe renal dysfunction ( value\<30ml/min;), liver dysfunction and thrombocytopenia
  8. Patients with severe valve disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension;
  9. Not suitable for clinical research:

    1. Currently participating in another study that may affect the primary endpoint
    2. Pregnant and lactating women;
    3. Known allergy to drugs that may be used in the study;
    4. Unable to comply with the trial protocol or follow-up requirements; Or the researcher believes that participating in the trial may result in patients facing greater risks.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
840 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Immediate complete revascularisation

    Device: PCI-immediate complete revascularisation

  • Active comparator
    Control group

    Staged complete revascularisation

    Device: PCI-staged complete revascularisation

Interventions

  • DevicePCI-immediate complete revascularisation

    In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.

  • DevicePCI-staged complete revascularisation

    In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.

06

What researchers measure

Primary outcomes

  1. MACCE

    The primary outcome was the composite of all-cause mortality, myocardial infarction, any unplanned ischemia-driven revascularization, stroke or hospitalization for heart failure at 1 year after the index procedure.

    Time frame: At 1 year after the index procedure

Secondary outcomes

  1. MACCE

    The primary outcome was the composite of all-cause mortality, myocardial infarction, any unplanned ischemia-driven revascularization, stroke or hospitalization for heart failure at 1 year after the index procedure.

    Time frame: At 1 months, 6 months, 2 and 3 years after the index procedure

  2. All-cause mortality

    All-cause mortality (cardiovascular death, non- cardiovascular death, undetermined cause of death)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  3. Cardiovascular death

    Cardiovascular death

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  4. Myocardial Infarction

    Myocardial Infarction (Q-wave and non Q-wave MI)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  5. TVR: Target vessel revascularization

    TVR: Target vessel revascularization(Ischemia driven revascularization, or Non ischemic driven revascularization)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  6. Any coronary revascularization

    Any coronary revascularization (ischemic driven, non ischemic driven)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  7. Stent Thrombosis

    ARC-2 defines Stent Thrombosis: including confirmed and possible stent thrombosis within acute, subacute, and advanced time ranges

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  8. Stroke (Ischemic\hemorrhagic)

    Stroke (Ischemic\\hemorrhagic)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  9. Hospitalization for heart failure

    Hospitalization for heart failure

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

  10. Contrast-induced acute kidney injury

    Contrast-induced acute kidney injury

    Time frame: At 1 months after the index procedure

  11. Major bleeding

    Major bleeding (BARC 3-5)

    Time frame: At 1 months, 6 months, 1, 2 and 3 years after the index procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 37 months is close to that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2023
First posted
Aug 1, 2023
StartActual
Nov 11, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05967663
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Nov 11, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 4, 2023

Study contacts

Jun Pu, MD, PhD
Contact
pujun310@hotmail.com
86-21-68383477
Jun Pu, MD, PhD
principal investigator · Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion